Global Leukocyte Adhesion Deficiency Management Market Report 2024

Leukocyte Adhesion Deficiency Management Global Market Report 2024 – By Treatment (Hematopoietic Stem Cell Transplantation, Recombinant Human Interferon-Gamma Treatment, Prophylactic Immunoglobulin Therapy, Antimicrobial Therapy, Prophylactic Therapy, Fucose Supplementation, Monoclonal Antibodies, Coagulation Factors), By Diagnosis (Blood Test, Genetic Testing, Biopsy, Other Types), By End-Users (Hospitals, Specialty Clinics, Other End-Users ) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : 175 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Leukocyte Adhesion Deficiency Management Market Definition And Segments

Leukocyte adhesion deficiency (LAD) is a rare genetic disorder affecting the immune system's ability to fight infections. It is characterized by a defect in the adhesion (stickiness) of white blood cells, specifically neutrophils, essential for the body's defense against bacteria and fungi. Management of leukocyte adhesion deficiency typically involves a multidisciplinary approach and focuses on preventing and treating infections and addressing the underlying immune system dysfunction.

The main types of treatment in leukocyte adhesion deficiency management are hematopoietic stem cell transplantation, recombinant human interferon-gamma treatment, prophylactic immunoglobulin therapy, antimicrobial therapy, prophylactic therapy, fucose supplementation, monoclonal antibodies, and coagulation factors. Hematopoietic stem cell transplantation refers to a medical procedure where stem cells from the bone marrow or blood are transplanted into a patient to replace damaged or diseased blood-forming cells. Treatment and diagnostics such as blood tests, genetic testing, biopsies, and others are provided by end users such as hospitals, specialty clinics, and others.

The leukocyte adhesion deficiency management market covered in this report is segmented –

1) By Treatment: Hematopoietic Stem Cell Transplantation, Recombinant Human Interferon-Gamma Treatment, Prophylactic Immunoglobulin Therapy, Antimicrobial Therapy, Prophylactic Therapy, Fucose Supplementation, Monoclonal Antibodies, Coagulation Factors

2) By Diagnosis: Blood Test, Genetic Testing, Biopsy, Other Types

3) By End-Users: Hospitals, Specialty Clinics, Other End-Users

The leukocyte adhesion deficiency management market size has grown strongly in recent years. It will grow from $7.48 billion in 2023 to $8.07 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increased awareness and education, genetic testing advancements, orphan drug designations, global health policies, patient advocacy groups, pediatric healthcare advancements.

The leukocyte adhesion deficiency management market size is expected to see strong growth in the next few years. It will grow to $10.46 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to precision medicine approaches, emergence of novel therapeutics, expanded genetic testing accessibility, patient-centric drug development, advancements in immunomodulatory therapies. Major trends in the forecast period include stem cell transplantation innovations, integration of supportive therapies, telemedicine for remote consultations, collaboration and research networks, integration of biomarker technologies.

Leukocyte Adhesion Deficiency Management Market Grows In Response To Rising Prevalence Of Primary Immunodeficiency.

The rising prevalence of primary immunodeficiency is expected to propel the growth of the leukocyte adhesion deficiency management market going forward. Primary immunodeficiency (PID) is a group of inherited disorders that weaken the body's immune system, making individuals more susceptible to infections and illnesses due to defects in their immune responses. Management of leukocyte adhesion deficiency benefits primary immunodeficiency by advancing the understanding of immune system disorders and potentially leading to improved diagnostic tools and therapies to help both conditions. For instance, in April 2023, according to the Peace Hospital, an India-based multi-specialty hospital, the data collected from World Primary Immunodeficiency (WPI) Awareness Week 2023 shows that primary immunodeficiency (PI) affects an estimated 60 lakh people globally, and 70% to 90% of people have undiagnosed primary immunodeficiency. Therefore, the rising prevalence of primary immunodeficiency will drive the growth of the leukocyte adhesion deficiency management market.

Rising Prevalence Of Spinal Cord Injuries Fuels Growth In Leukocyte Adhesion Deficiency Management Market

The increasing prevalence of spinal cord injuries is expected to propel the growth of the leukocyte adhesion deficiency management market going forward. Spinal cord injury is a condition that occurs when there is damage to any part of the spinal cord or nerves at the end of the spinal canal (cauda equina). Spinal cord injury can lead to autonomic dysfunction, including hyperhidrosis. It is related to sympathetic overactivity of the cephalad portion of the spinal cord immediately below the zone of injury. For instance, in March 2022, according to the National Spinal Cord Injury Statistical Center (NSCISC), a US-based department that supports and directs the collection, management, and analysis of spinal cord injury research databases, it is estimated that the annual incidence of traumatic spinal cord injury (SCI) is approximately 54 cases per one million people in the United States, which equals about 18,000 new SCI (spinal cord injury) cases each year. Further, the estimated number of people with SCI living in the United States is approximately 299,000, ranging from 253,000 to 378,000. Therefore, the increasing prevalence of spinal cord injuries drives the growth of the leukocyte adhesion deficiency management market.

Major companies operating in the leukocyte adhesion deficiency management market report are F. Hoffmann-La Roche Ltd., Novartis AG, GlaxoSmithKline PLC, Gilead Sciences Inc., Teva Pharmaceuticals Industries Limited, CSL Behring LLC, Vertex Pharmaceuticals Inc., Grifols International S.A., Aurobindo Pharma Ltd., BioMarin Pharmaceutical Inc., Cadila Healthcare Ltd., Ipca Laboratories Ltd., Sana Biotechnology Inc., Rocket Pharmaceuticals Inc., PT Sanbe Farma, Magenta Therapeutics Inc., Avalo Therapeutics Inc., Aspen Neuroscience Inc., Sandoz International GmbH, Orpha Labs Inc., Swiss Pharm Holding AG, Rubius Therapeutics Inc., Enochian Biosciences Inc., Sigma-Aldrich LLC, Bluebird Bio Inc.

Challenges Posed By High Treatment Costs In The Leukocyte Adhesion Deficiency (LAD) Management Market

The high cost of treatment is expected to limit the growth of the leukocyte adhesion deficiency management market going forward. Leukocyte Adhesion Deficiency (LAD) is a rare disorder of leukocyte adhesion and migration resulting from mutations in the ITGB2 gene. The treatment options for LAD are limited, and the cost of treatment can be high. The high cost of treatment for LAD can impact the management of the disease by restricting accessibility to treatment, causing hesitancy to try new treatments, and making it challenging to access consultations with specialists. For instance, according to DVC Stem, a UK-based stem cell treatment clinic, the expense associated with a stem cell transplant (treatment for leukocyte adhesion deficiency) fluctuates based on the required treatment type, with costs spanning from $15,000 to $75,000, treatment expenses fell within the $10,000 to $40,000 range, and that patients might incur expenditures ranging from less than $5,000 to more than $50,000. Therefore, the high cost of treatment limits the growth of the leukocyte adhesion deficiency management market.

Leading Companies In The Leukocyte Adhesion Deficiency Management Market Focus On Advanced Therapies Like Rp-L201 To Improve Treatment For Lad-I

Major companies operating in the leukocyte adhesion deficiency management market are focused on developing novel treatments and therapies, such as RP-L201, to address the underlying genetic defects and improve the quality of life for affected individuals. Regenerative Medicine Advanced Therapy (RMAT) for RP-L201 supports the efficient development of advanced gene therapy for treating leukocyte adhesion deficiency-I (LAD-I). For instance, in March 2021, Rocket Pharmaceuticals, Inc., a US-based clinical-stage company, received the U.S. Food and Drug Administration (FDA) designation for Regenerative Medicine Advanced Therapy (RMAT) (RP-L201). The RMAT designation was obtained based on promising preliminary safety and efficacy data from RP-L201's ongoing Phase 1/2 clinical trial. The RMAT designation was created to aid in developing and approving regenerative medicine products such as cell and gene therapies. The designation is given to an investigational product that has the potential to treat, alter, reverse, or cure a serious or life-threatening disease or condition and is supported by preliminary clinical evidence demonstrating its ability to address an unmet medical need.

JMF And Veritas Intercontinental Join Forces For Genome Sequencing Advancements In Primary Immunodeficiency

In February 2023, Jeffrey Modell Foundation (JMF), a US-based nonprofit company for primary immunodeficiency, collaborated with Veritas Intercontinental to advance genome and exome sequencing for immunological disorders. The collaboration aims to enhance precise diagnosis and treatment by globally identifying gene abnormalities in primary immunodeficiency, such as leukocyte adhesion deficiency. Veritas Intercontinental is a Spain-based healthcare solutions company specializing in genome sequencing and analytic services.

North America was the largest region in the leukocyte adhesion deficiency management market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukocyte adhesion deficiency management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the leukocyte adhesion deficiency management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The leukocyte adhesion deficiency management market consists of revenues earned by entities by providing services such as gene therapy, granulocyte transfusions, nutrition, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The leukocyte adhesion deficiency management market also includes sales of antibiotics such as trimethoprim and sulfamethoxazole. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The leukocyte adhesion deficiency management market research report is one of a series of new reports from The Business Research Company that provides leukocyte adhesion deficiency management market statistics, including leukocyte adhesion deficiency management industry global market size, regional shares, competitors with a leukocyte adhesion deficiency management market share, detailed leukocyte adhesion deficiency management market segments, market trends and opportunities, and any further data you may need to thrive in the leukocyte adhesion deficiency management industry. This leukocyte adhesion deficiency management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Leukocyte Adhesion Deficiency Management Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $8.07 billion
Revenue Forecast In 2033 $10.46 billion
Growth Rate CAGR of 6.7% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Treatment: Hematopoietic Stem Cell Transplantation, Recombinant Human Interferon-Gamma Treatment, Prophylactic Immunoglobulin Therapy, Antimicrobial Therapy, Prophylactic Therapy, Fucose Supplementation, Monoclonal Antibodies, Coagulation Factors
2) By Diagnosis: Blood Test, Genetic Testing, Biopsy, Other Types
3) By End-Users: Hospitals, Specialty Clinics, Other End-Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled F. Hoffmann-La Roche Ltd.; Novartis AG; GlaxoSmithKline Plc; Gilead Sciences Inc; Teva Pharmaceuticals Industries Limited; CSL Behring LLC; Vertex Pharmaceuticals Inc.; Grifols International S.A.; Aurobindo Pharma Ltd.; BioMarin Pharmaceutical Inc.; Cadila Healthcare Ltd.; Ipca Laboratories Ltd; Sana Biotechnology Inc.; Rocket Pharmaceuticals Inc.; PT Sanbe Farma; Magenta Therapeutics Inc; Avalo Therapeutics Inc.; Aspen Neuroscience Inc.; Sandoz International GmbH; Orpha Labs Inc.; Swiss Pharm Holding AG; Rubius Therapeutics Inc.; Enochian Biosciences Inc.; Sigma-Aldrich LLC; Bluebird Bio Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Leukocyte Adhesion Deficiency Management Market Characteristics

    3. Leukocyte Adhesion Deficiency Management Market Trends And Strategies

    4. Leukocyte Adhesion Deficiency Management Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Leukocyte Adhesion Deficiency Management Market Size and Growth

    5.1. Global Leukocyte Adhesion Deficiency Management Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Leukocyte Adhesion Deficiency Management Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Leukocyte Adhesion Deficiency Management Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Leukocyte Adhesion Deficiency Management Market Segmentation

    6.1. Global Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hematopoietic Stem Cell Transplantation

    Recombinant Human Interferon-Gamma Treatment

    Prophylactic Immunoglobulin Therapy

    Antimicrobial Therapy

    Prophylactic Therapy

    Fucose Supplementation

    Monoclonal Antibodies

    Coagulation Factors

    6.2. Global Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Blood Test

    Genetic Testing

    Biopsy

    Other Types

    6.3. Global Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Specialty Clinics

    Other End-Users

    7. Leukocyte Adhesion Deficiency Management Market Regional And Country Analysis

    7.1. Global Leukocyte Adhesion Deficiency Management Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Leukocyte Adhesion Deficiency Management Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Leukocyte Adhesion Deficiency Management Market

    8.1. Asia-Pacific Leukocyte Adhesion Deficiency Management Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Leukocyte Adhesion Deficiency Management Market

    9.1. China Leukocyte Adhesion Deficiency Management Market Overview

    9.2. China Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Leukocyte Adhesion Deficiency Management Market

    10.1. India Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Leukocyte Adhesion Deficiency Management Market

    11.1. Japan Leukocyte Adhesion Deficiency Management Market Overview

    11.2. Japan Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Leukocyte Adhesion Deficiency Management Market

    12.1. Australia Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Leukocyte Adhesion Deficiency Management Market

    13.1. Indonesia Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Leukocyte Adhesion Deficiency Management Market

    14.1. South Korea Leukocyte Adhesion Deficiency Management Market Overview

    14.2. South Korea Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Leukocyte Adhesion Deficiency Management Market

    15.1. Western Europe Leukocyte Adhesion Deficiency Management Market Overview

    15.2. Western Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Leukocyte Adhesion Deficiency Management Market

    16.1. UK Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Leukocyte Adhesion Deficiency Management Market

    17.1. Germany Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Leukocyte Adhesion Deficiency Management Market

    18.5. France Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Leukocyte Adhesion Deficiency Management Market

    19.9. Italy Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Leukocyte Adhesion Deficiency Management Market

    20.13. Spain Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Leukocyte Adhesion Deficiency Management Market

    21.1. Eastern Europe Leukocyte Adhesion Deficiency Management Market Overview

    21.2. Eastern Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Leukocyte Adhesion Deficiency Management Market

    22.1. Russia Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Leukocyte Adhesion Deficiency Management Market

    23.1. North America Leukocyte Adhesion Deficiency Management Market Overview

    23.2. North America Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Leukocyte Adhesion Deficiency Management Market

    24.1. USA Leukocyte Adhesion Deficiency Management Market Overview

    24.2. USA Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Leukocyte Adhesion Deficiency Management Market

    25.1. Canada Leukocyte Adhesion Deficiency Management Market Overview

    25.2. Canada Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Leukocyte Adhesion Deficiency Management Market

    26.1. South America Leukocyte Adhesion Deficiency Management Market Overview

    26.2. South America Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Leukocyte Adhesion Deficiency Management Market

    27.1. Brazil Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Leukocyte Adhesion Deficiency Management Market

    28.1. Middle East Leukocyte Adhesion Deficiency Management Market Overview

    28.2. Middle East Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Leukocyte Adhesion Deficiency Management Market

    29.1. Africa Leukocyte Adhesion Deficiency Management Market Overview

    29.2. Africa Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Leukocyte Adhesion Deficiency Management Market Competitive Landscape And Company Profiles

    30.1. Leukocyte Adhesion Deficiency Management Market Competitive Landscape

    30.2. Leukocyte Adhesion Deficiency Management Market Company Profiles

    30.2.1. F. Hoffmann-La Roche Ltd.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Novartis AG

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. GlaxoSmithKline Plc

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Gilead Sciences Inc

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Teva Pharmaceuticals Industries Limited

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Leukocyte Adhesion Deficiency Management Market Other Major And Innovative Companies

    31.1. CSL Behring LLC

    31.2. Vertex Pharmaceuticals Inc.

    31.3. Grifols International S.A.

    31.4. Aurobindo Pharma Ltd.

    31.5. BioMarin Pharmaceutical Inc.

    31.6. Cadila Healthcare Ltd.

    31.7. Ipca Laboratories Ltd

    31.8. Sana Biotechnology Inc.

    31.9. Rocket Pharmaceuticals Inc.

    31.10. PT Sanbe Farma

    31.11. Magenta Therapeutics Inc

    31.12. Avalo Therapeutics Inc.

    31.13. Aspen Neuroscience Inc.

    31.14. Sandoz International GmbH

    31.15. Orpha Labs Inc.

    32. Global Leukocyte Adhesion Deficiency Management Market Competitive Benchmarking

    33. Global Leukocyte Adhesion Deficiency Management Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Leukocyte Adhesion Deficiency Management Market

    35. Leukocyte Adhesion Deficiency Management Market Future Outlook and Potential Analysis

    35.1 Leukocyte Adhesion Deficiency Management Market In 2028 - Countries Offering Most New Opportunities

    35.2 Leukocyte Adhesion Deficiency Management Market In 2028 - Segments Offering Most New Opportunities

    35.3 Leukocyte Adhesion Deficiency Management Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Leukocyte Adhesion Deficiency Management Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Leukocyte Adhesion Deficiency Management Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 75: Novartis AG Financial Performance
  • Table 76: GlaxoSmithKline Plc Financial Performance
  • Table 77: Gilead Sciences Inc Financial Performance
  • Table 78: Teva Pharmaceuticals Industries Limited Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Leukocyte Adhesion Deficiency Management Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Leukocyte Adhesion Deficiency Management Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Leukocyte Adhesion Deficiency Management Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Leukocyte Adhesion Deficiency Management Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Leukocyte Adhesion Deficiency Management Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 75: Novartis AG Financial Performance
  • Figure 76: GlaxoSmithKline Plc Financial Performance
  • Figure 77: Gilead Sciences Inc Financial Performance
  • Figure 78: Teva Pharmaceuticals Industries Limited Financial Performance
Forecasting Till 2030: Opportunities And Strategies In The Global Value Based Care Payment Market – Includes Value Based Care Payment Market Analysis
Read More
How Will The Nuclear Medicine Market Grow In 2022?
Read More
What Is The Pediatric Imaging Market Overview In 2022?
Read More
Latest Healthcare Technology Management Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the hospital acquired infection control market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the multiplex assays market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the healthcare it consulting market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the renal biomarkers market research report 2022 with industry size, share, segments and market growth
Read More
Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2024 – By Treatment (Anti-retroviral Therapy, Antiviral Or Anti-John Cunningham Virus (JCV), Other Symptomatic), By Indication (HIV Or AIDS, Organ Transplantation, Multiple Sclerosis, Hematologic Malignancies), By Route of Administration (Oral, Parenteral, Other Routes Of Administration), By End-Users (Hospitals, Homecare, Specialty Centers, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Merkel Cell Carcinoma Treatment Global Market Report 2024 – By Diagnosis (Physical Examination, Sentinel Node Biopsy, Imaging Test), By Therapy (Surgical Excision, Micrographic Surgery, Radiation, Chemotherapy, Other Therapies), By Route Of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By End User (Hospitals, Homecare, Specialty Centers, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Basal Cell Carcinoma Treatment Global Market Report 2024 – By Treatment (Surgery, Medication, Other Treatments), By Route Of Administration (Oral, Parenteral, Other Route Of Administrations), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By End-User (Hospitals, Specialty Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Crohn's Disease (CD) Treatment Global Market Report 2024 – By Drug Type (Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Encephalitis Treatment Global Market Report 2024 – By Disease Type (Primary Encephalitis, Secondary Encephalitis), By Treatment (Antiviral Agents, Steroid Injections, Antibiotics, Immunoglobulin Therapy, Plasmapheresis, Other Treatments), By Route of Administration (Oral, Parenteral, Other Routes Of Administrations), By Diagnosis (Imaging Tests, Blood Tests, Biopsy, Other Diagnosis), By End-User (Hospitals, Specialty Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Epidural Abscess Treatment Global Market Report 2024 – By Type (Intracranial, Intraspinal), By Treatment (Antifungal, Antibiotics, Surgery), By End-User (Hospital, Pharmacy, Specialty Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Keloids Treatment Global Market Report 2024 – By Treatment (Radiation Therapy, Cryo Therapy, Surgical Treatment, Laser Treatment, Steroid Injections, Interferon, Other Treatments), By Product Type (Elastic Wraps, Sprays, Ointment, Creams, Oils, Topical Gels And Gel Sheets, Other Products), By Route Of Administration (Oral, Parenteral), By End User (Hospitals, Homecare, Dermatology Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Chronic Myeloid Leukemia Treatment Global Market Report 2024 – By Type (Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy, Stem Cell Transplant), By Route of Administration (Oral, Parenteral, Other Route of Administrations), By End-User (Hospitals, Specialty Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the leukocyte adhesion deficiency management market?

Leukocyte adhesion deficiency (LAD) is a rare genetic disorder affecting the immune system's ability to fight infections. It is characterized by a defect in the adhesion (stickiness) of white blood cells, specifically neutrophils, essential for the body's defense against bacteria and fungi. Management of leukocyte adhesion deficiency typically involves a multidisciplinary approach and focuses on preventing and treating infections and addressing the underlying immune system dysfunction. For further insights on the leukocyte adhesion deficiency management market, request a sample here

How will the leukocyte adhesion deficiency management market drivers and restraints affect the leukocyte adhesion deficiency management market dynamics? What forces will shape the leukocyte adhesion deficiency management industry going forward?

The leukocyte adhesion deficiency management market major growth driver - leukocyte adhesion deficiency management market grows in response to rising prevalence of primary immunodeficiency.. For further insights on the leukocyte adhesion deficiency management market, request a sample here

What is the forecast market size or the forecast market value of the leukocyte adhesion deficiency management market?

The leukocyte adhesion deficiency management market size has grown strongly in recent years. It will grow from $7.48 billion in 2023 to $8.07 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increased awareness and education, genetic testing advancements, orphan drug designations, global health policies, patient advocacy groups, pediatric healthcare advancements.. The leukocyte adhesion deficiency management market size is expected to see strong growth in the next few years. It will grow to $10.46 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to precision medicine approaches, emergence of novel therapeutics, expanded genetic testing accessibility, patient-centric drug development, advancements in immunomodulatory therapies.. Major trends in the forecast period include stem cell transplantation innovations, integration of supportive therapies, telemedicine for remote consultations, collaboration and research networks, integration of biomarker technologies.. For further insights on the leukocyte adhesion deficiency management market, request a sample here

How is the leukocyte adhesion deficiency management market segmented?

The leukocyte adhesion deficiency management market is segmented
1) By Treatment: Hematopoietic Stem Cell Transplantation, Recombinant Human Interferon-Gamma Treatment, Prophylactic Immunoglobulin Therapy, Antimicrobial Therapy, Prophylactic Therapy, Fucose Supplementation, Monoclonal Antibodies, Coagulation Factors
2) By Diagnosis: Blood Test, Genetic Testing, Biopsy, Other Types
3) By End-Users: Hospitals, Specialty Clinics, Other End-Users For further insights on the leukocyte adhesion deficiency management market, request a sample here

Which region has the largest share of the leukocyte adhesion deficiency management market? What are the other regions covered in the report?

North America was the largest region in the leukocyte adhesion deficiency management market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukocyte adhesion deficiency management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the leukocyte adhesion deficiency management market, request a sample here.

Who are the major players in the leukocyte adhesion deficiency management market?

Major companies operating in the leukocyte adhesion deficiency management market report are F. Hoffmann-La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Gilead Sciences Inc, Teva Pharmaceuticals Industries Limited, CSL Behring LLC, Vertex Pharmaceuticals Inc., Grifols International S.A., Aurobindo Pharma Ltd., BioMarin Pharmaceutical Inc., Cadila Healthcare Ltd., Ipca Laboratories Ltd, Sana Biotechnology Inc., Rocket Pharmaceuticals Inc., PT Sanbe Farma, Magenta Therapeutics Inc, Avalo Therapeutics Inc., Aspen Neuroscience Inc., Sandoz International GmbH, Orpha Labs Inc., Swiss Pharm Holding AG, Rubius Therapeutics Inc., Enochian Biosciences Inc., Sigma-Aldrich LLC, Bluebird Bio Inc. For further insights on the leukocyte adhesion deficiency management market, request a sample here.

What are the key trends in the leukocyte adhesion deficiency management market?

Major trend in the leukocyte adhesion deficiency management market - Leading Companies In The Leukocyte Adhesion Deficiency Management Market Focus On Advanced Therapies Like Rp-L201 To Improve Treatment For Lad-I. For further insights on the leukocyte ad request a sample here.

What are the major opportunities in the leukocyte adhesion deficiency management market? What are the strategies for the leukocyte adhesion deficiency management market?

For detailed insights on the major opportunities and strategies in the leukocyte adhesion deficiency management market, request a sample here.

How does the leukocyte adhesion deficiency management market relate to the overall economy and other similar markets?

For detailed insights on leukocyte adhesion deficiency management market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the leukocyte adhesion deficiency management industry?

For detailed insights on the mergers and acquisitions in the leukocyte adhesion deficiency management industry, request a sample here.

What are the key dynamics influencing the leukocyte adhesion deficiency management market growth? SWOT analysis of the leukocyte adhesion deficiency management market.

For detailed insights on the key dynamics influencing the leukocyte adhesion deficiency management market growth and SWOT analysis of the leukocyte adhesion deficiency management industry, request a sample here.